United States · 
Who invested in Silver Creek Pharmaceuticals?
Silver Creek Pharmaceuticals's investors include Goldman Sachs and JP Morgan.
United States · Venture startup
Who invested in Silver Creek Pharmaceuticals
Funding summaryUpdated 26 Oct 2026
$9.2Mraised across 1 round since 2022, from 1 source
- Latest round
- Venture, $9.2MFeb 2022
- Investors
- 2
The rounds
- Feb 2022
Founders and team
From Silver Creek Pharmaceuticals's own website and the SEC filings it signed: 6 on the team.
- Andrea StukelHead of Clinical Development
- Walter OlsenHead of CMC
- Tim ThrosbyChair
- Kris D. KuchenbeckerExecutive Officeri
- Lakhmir D. ChawlaExecutive Officeri
- Timothy ThrosbyExecutive Officer, Directori
On the board, as filediJames D. MarksMark AgneNick J. TaylorThomas J. Murtagh
Everyone who backed them
Missing a round, or an investor who was in one? Tell us.
Also claim to have backed them
This firm lists Silver Creek Pharmaceuticals as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.
Quick answers about Silver Creek Pharmaceuticals
How much has Silver Creek Pharmaceuticals raised?
Silver Creek Pharmaceuticals has raised $9.2M across 1 round since 2022.
When did Silver Creek Pharmaceuticals last raise?
Silver Creek Pharmaceuticals's most recent round was a Venture of $9.2M in Feb 2022.
What was Silver Creek Pharmaceuticals's biggest round?
Its most recent round, $9.2M in Feb 2022, is also its largest on record.
Who backed Silver Creek Pharmaceuticals first?
Silver Creek Pharmaceuticals's first round on record, in Feb 2022, was backed by Goldman Sachs and JP Morgan.
What stage is Silver Creek Pharmaceuticals at?
Silver Creek Pharmaceuticals's latest named round is a Venture, in Feb 2022.
Where is Silver Creek Pharmaceuticals based?
Silver Creek Pharmaceuticals is based in the United States.
Companies like Silver Creek Pharmaceuticals
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.